NASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $187.53 0.00 (0.00%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$187.00 -0.53 (-0.28%) As of 07/31/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Revolution Medicines Stock (NASDAQ:RVMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$186.15▼$192.0050-Day Range$144.19▼$192.6252-Week Range$34.00▼$194.56Volume1.49 million shsAverage Volume1.89 million shsMarket Capitalization$39.87 billionP/E RatioN/ADividend YieldN/APrice Target$144.67Consensus RatingModerate Buy Company Overview Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance. The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations. These candidates are being evaluated in various phases of clinical development across solid tumors, with the goal of delivering first-in-class or best-in-class therapies for patients with limited treatment options. Founded in 2015 and headquartered in Redwood City, California, Revolution Medicines operates research facilities in North America and collaborates with academic institutions and industry partners to accelerate innovation. The management team comprises experienced executives with deep expertise in oncology drug discovery, guiding the company’s strategic partnerships and clinical advancement efforts.AI Generated. May Contain Errors. Read More Revolution Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreRVMD MarketRank™: Revolution Medicines scored higher than 39% of companies evaluated by MarketBeat, and ranked 700th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 2 strong buy ratings, 18 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskRevolution Medicines has a consensus price target of $144.67, representing about 22.9% downside from its current price of $187.53.Amount of Analyst CoverageRevolution Medicines has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($7.92) to ($4.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -26.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -26.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 22.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.13% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 6.79.Change versus previous monthShort interest in Revolution Medicines has recently increased by 8.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. News and Social Media4.6 / 5News Sentiment1.39 News SentimentRevolution Medicines has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Revolution Medicines this week, compared to 8 articles on an average week.Search Interest23 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat Follows14 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,470,486.00 in company stock.Percentage Held by Insiders7.60% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Stock News HeadlinesRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 31 at 2:15 AM | americanbankingnews.comRevolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026July 29, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 3 at 1:00 AM | Porter & Company (Ad)Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?July 25, 2026 | finance.yahoo.comRevolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic CancerJuly 25, 2026 | finance.yahoo.comRevolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerJuly 22, 2026 | markets.businessinsider.comRevolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic CancerJuly 22, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and CVRx (CVRX)July 10, 2026 | theglobeandmail.comSee More Headlines RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $79.65 on January 1st, 2026. Since then, RVMD stock has increased by 135.4% and is now trading at $187.53. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.83) by $0.46. Read the conference call transcript. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $231 million in an IPO on Thursday, February 13th 2020. The company issued 14,000,000 shares at $16.00-$17.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include Handelsbanken Fonder AB (0.10%), Assenagon Asset Management S.A. (0.09%), Tema ETFs LLC (0.03%) and PensionDanmark Pensionsforsikringsaktieselskab. Insiders that own company stock include Thilo Schroeder, Stephen Michael Kelsey, Mark A Goldsmith, Margaret A Horn, Jack Anders, Xiaolin Wang, Lin Wei, Jeff Cislini, Sushil Patel and Barbara Weber. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/06/2026Today8/03/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 RVMD's financial health is in the Green zone, according to TradeSmith. RVMD has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RVMD CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees250Year Founded2014Price Target and Rating Average Price Target for Revolution Medicines$144.67 High Price Target$236.00 Low Price Target$70.00 Potential Upside/Downside-22.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($7.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.13 billion Net MarginsN/A Pretax MarginN/A Return on Equity-83.22% Return on Assets-59.06% Debt Debt-to-Equity Ratio0.19 Current Ratio6.80 Quick Ratio6.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.44 per share Price / Book22.22Miscellaneous Outstanding Shares212,596,000Free Float196,439,000Market Cap$39.87 billion OptionableOptionable Beta1.37 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RVMD) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
